Quadrant Capital Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Quadrant Capital Group’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,091	Closed	-$12.1K	–	2199
2026 Q1	$12.1K	Buy	1,091 +18	+2%	+$227	﹤0.01%	2148
2025 Q4	$17.8K	Hold	1,073	–	–	﹤0.01%	2039
2025 Q3	$12.6K	Buy	+1,073	New	+$11.1K	﹤0.01%	2099
2025 Q2	–	Sell	-84	Closed	-$527	–	2251
2025 Q1	$527	Buy	+84	New	+$510	﹤0.01%	2651
2023 Q1	–	Sell	-212	Closed	-$2.38K	–	2773
2022 Q4	$2.38K	Hold	212	–	–	﹤0.01%	2366
2022 Q3	$2K	Hold	212	–	–	﹤0.01%	2407
2022 Q2	$2K	Buy	+212	New	+$2.18K	﹤0.01%	2254
2022 Q1	–	Sell	-49	Closed	-$1K	–	2646
2021 Q4	$1K	Buy	+49	New	+$1.15K	﹤0.01%	2372

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Quadrant Capital Group's PHAT Position: Q2 2026 in Review

Quadrant Capital Group sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 1,091 shares — an estimated $12.1K sold.

Quadrant Capital Group first reported a position in PHAT in Q4 2021 and held it in 8 quarters. The position peaked at $17.8K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Quadrant Capital Group reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 1,091 Phathom Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
Quadrant Capital Group first reported a position in Phathom Pharmaceuticals in Q4 2021 and held it in 8 quarters.
Quadrant Capital Group's Phathom Pharmaceuticals position peaked at $17.8K in Q4 2025.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.